3 transcripts
REGN
Earnings call transcript
NASDAQ
2024 Q1
2 May 24
is delivering on its promise of extending the duration between treatments, but the majority of patients achieving this goal. Retina specialists
REGN
Earnings call transcript
NASDAQ
2023 Q4
2 Feb 24
prescription share in the United States across all 5 of its approved indications.
We also had a major breakthrough in chronic obstructive pulmonary
REGN
Earnings call transcript
NASDAQ
2023 Q2
3 Aug 23
. These data demonstrated that the vast majority aflibercept 8-milligram patients randomized to the 12-week and 16-week dosing intervals continued
- Prev
- 1
- Next